Table IV.

Reductions in Mean SBP and DBP Observed After 8 Weeks of Treatment: Results From the Factorial Studies for the Fixed‐Dose Combinations of ARBs With HCTZ*

		Mean Absolute Change in BP (mm Hg)		Mean Placebo‐Corrected Change in BP (mm Hg)
Drug Combination	Doses	DBP	SBP	DBP	SBP
Irbesartan/HCTZ 22	37.5 mg/6.25 mg	−8.1	−10.2	−4.6	−7.9
	100 mg/6.25 mg	−10.0	−11.9	−6.5	−9.6
	300 mg/6.25 mg	−13.2	−17.2	−9.7	−14.9
	37.5 mg/12.5 mg	−9.0	−14.7	−5.5	−12.4
	100 mg/12.5 mg**††	−11.9	−14.9	−8.4	−12.6
	300 mg/12.5 mg††	−15.0	−15.9	−11.5	−13.6
	37.5 mg/25 mg	−11.7	−16.8	−8.2	−14.5
	100 mg/25 mg	−13.8	−21.5	−10.3	−19.2
	300 mg/25 mg††	−14.4	−23.1	−10.9	−20.8
Olmesartan/HCTZ 23	10 mg/12.5 mg	−13.5	−17.4	−5.3	−14.1
	20 mg/12.5 mg††	−16.4	−20.1	−8.2	−16.8
	40 mg/12.5 mg††	−17.3	−20.6	−9.1	−17.3
	10 mg/25 mg	−17.1	−23.0	−8.9	−19.7
	20 mg/25 mg	−20.0	−27.1	−11.8	−23.8
	40 mg/25 mg††	−21.9	−26.8	−13.7	−23.5
Telmisartan/HCTZ†24	40 mg/12.5 mg††	−12.6	−18.8	−8.8	−15.9
	80 mg/12.5 mg††	−14.9	−23.9	−11.1	−21.0
Valsartan/HCTZ 25 , 41	80 mg/12.5 mg††	−11.8	−16.5	−7.7	−14.6
	160 mg/12.5 mg††	−13.5	−17.7	−9.4	−15.8
	80 mg/25 mg	−15.3	−21.1	−11.2	−19.2
	160 mg/25 mg††	−15.3	−22.4	−11.2	−20.5
SBP=systolic blood pressure; DBP=diastolic blood pressure; ARB=angiotensin receptor blocker; HCTZ=hydrochlorothiazide; BP=blood pressure; *data are mean changes in DBP and SBP at end point (or last observation carried forward) in the intent‐to‐treat population for studies involving olmesartan, telmisartan, and valsartan; the irbesartan study provided data on the population of patients who completed the study and/or had Week 8 BP readings; **the dose combination evaluated in the irbesartan factorial study was 100 mg/12.5 mg; however, the marketed combination is 150 mg/12.5 mg; †the telmisartan study used supine BP measurements and the other studies used sitting BP measurements; ††approved US dosages